Skip to main content
Premium Trial:

Request an Annual Quote

BioCommerce Week s Index to the Diversified Molecular Biology Tools Companies: Jan 13, 2005

Invitrogen and Waters Gain After JPMorgan Presentations; Thermo Falls

Shares in Invitrogen and Waters Corporation closed up on Tuesday as company officers presented a positive outlook early in the week at the annual JPMorgan Healthcare Conference in San Francisco this week.

Invitrogen’s shares were up 1.5 percent for the five-day period tracked by the BioCommerce Week Index, while Waters jumped 4.8 percent for the same period.

Thermo Electron, which presented to the conference on Tuesday afternoon, saw its shares fall 1.6 percent.

Becton Dickinson, Applied Biosystems, PerkinElmer, and Agilent Technologies were to present at the conference on Wednesday, while Beckman Coulter and Bio-Rad Laboratories were slated to present on Thursday.

For the week, Stratagene saw its shares drop 11 percent, erasing last week’s gain of 10 percent, followed by Agilent, Bruker, and PerkinElmer with share-price losses of 4 percent.

After two weeks of losses, the BioCommerce Week Index closed up a fraction of a percent at 34.22 as seven of the 15 companies saw share-price gains.

Overall, the index outperformed the Dow, which finished down a fraction of a percent for the week; the S&P 500, which dropped by a half a percentage for the same period; the Nasdaq index, which was down just over 1 percent; and the Amex pharma index, which was down close to 1 percent. The Amex biotechnology index was up 1 percent.

Upcoming Financial Conferences:

  • Needham Growth Conference,
    Jan. 11-15 (New York City)
    Jan. 13: Thermo Electron
  • PiperJaffray Healthcare,
    Jan. 25-27 (New York City)
    Jan. 25: Beckman Coulter
    Jan. 26: Invitrogen.
    Jan. 27: Becton Dickinson, Applied Biosystems.
  • Merrill Lynch 2005 Global Drug, Device and Biotechnology Conference,
    Feb. 8-10 (New York City)
  • Biotechnology Industry Organization CEO and Investor Conference,
    Feb. 23-24 (New York City)
  • Lehman Brothers’ Global Healthcare Conference,
    Mar. 30 — Apr. 1 (Miami Beach, Fla.)
File Attachments
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.